Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 200 of 2051 entries
View as:

Treatment of Patients With Anxiety Disorder (0777-022)

Phase: N/A Priority: Normal
NCT ID: NCT00539578 Org: User:
Start: 09/30/02 End: 02/28/03 Due: 02/28/04

A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

Phase: N/A Priority: Normal
NCT ID: NCT01010906 Org: User:
Start: 07/01/09 End: 06/21/10 Due: 06/21/11

A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00696709 Org: User:
Start: 12/12/08 End: 11/16/09 Due: 11/16/10

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Phase: N/A Priority: Normal
NCT ID: NCT00561080 Org: User:
Start: 10/26/07 End: 06/03/09 Due: 06/03/10

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Phase: N/A Priority: Normal
NCT ID: NCT00989079 Org: User:
Start: 10/16/09 End: 12/11/09 Due: 12/11/10

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Phase: N/A Priority: Normal
NCT ID: NCT00527943 Org: User:
Start: 12/01/07 End: 07/01/11 Due: 07/01/12

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Phase: N/A Priority: Normal
NCT ID: NCT04976634 Org: User:
Start: 08/18/21 End: 03/22/27 Due: 03/22/28

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

Phase: N/A Priority: Normal
NCT ID: NCT02037984 Org: User:
Start: 01/28/14 End: 07/01/16 Due: 07/01/17

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Phase: N/A Priority: Normal
NCT ID: NCT00039871 Org: User:
Start: 05/31/02 End: 09/30/07 Due: 09/30/08

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

Phase: N/A Priority: Normal
NCT ID: NCT00371761 Org: User:
Start: 09/30/06 End: 02/28/09 Due: 02/28/10

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Phase: N/A Priority: Normal
NCT ID: NCT02478398 Org: User:
Start: 07/20/15 End: 11/19/18 Due: 11/19/19

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Phase: N/A Priority: Normal
NCT ID: NCT03449147 Org: User:
Start: 03/15/18 End: 10/30/20 Due: 10/30/21

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Phase: N/A Priority: Normal
NCT ID: NCT04624204 Org: User:
Start: 12/08/20 End: 10/28/27 Due: 10/28/28

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Phase: N/A Priority: Normal
NCT ID: NCT04135352 Org: User:
Start: 11/04/19 End: 08/24/22 Due: 08/24/23

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Phase: N/A Priority: Normal
NCT ID: NCT00722371 Org: User:
Start: 09/05/08 End: 03/25/11 Due: 03/25/12

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Phase: N/A Priority: Normal
NCT ID: NCT00042029 Org: User:
Start: 06/18/02 End: 10/03/03 Due: 10/03/04

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Phase: N/A Priority: Normal
NCT ID: NCT03797326 Org: User:
Start: 02/12/19 End: 10/28/24 Due: 10/28/25

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Phase: N/A Priority: Normal
NCT ID: NCT04210115 Org: User:
Start: 02/28/20 End: 02/01/27 Due: 02/01/28

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Phase: N/A Priority: Normal
NCT ID: NCT04980872 Org: User:
Start: 11/02/21 End: 02/07/30 Due: 02/07/31

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Phase: N/A Priority: Normal
NCT ID: NCT01462266 Org: User:
Start: 01/13/12 End: 06/07/13 Due: 06/07/14

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Phase: N/A Priority: Normal
NCT ID: NCT01582308 Org: User:
Start: 06/21/12 End: 12/14/12 Due: 12/14/13

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Phase: N/A Priority: Normal
NCT ID: NCT03230916 Org: User:
Start: 11/06/17 End: 08/11/20 Due: 08/11/21

Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00551330 Org: User:
Start: 09/30/07 End: 05/31/10 Due: 05/31/11

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Phase: N/A Priority: Normal
NCT ID: NCT06829199 Org: User:
Start: 03/26/25 End: 03/18/31 Due: 03/18/32

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Phase: N/A Priority: Normal
NCT ID: NCT06395090 Org: User:
Start: 01/15/25 End: 06/30/29 Due: 06/30/30